Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Radaelli, Antonia ^a   Pozzi, Eleana ^a   Pacchioni, Sole ^a   Zanotto, Carlo ^a   Morghen, Carlo D G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FOWLPOX VIRUS VECTOR; GAMMA INTERFERON; INTERLEUKIN 4; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS VECTOR; CELL EXTRACT; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FOWLPOX VIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; RABBIT; TUMOR REGRESSION; UTERINE CERVIX CARCINOMA; VIRUS RECOMBINANT; ANIMAL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; CHICKEN; FEMALE; GENETIC RECOMBINATION; GENETICS; HUMAN; IMMUNOLOGY; TH1 CELL; TH2 CELL; TUMOR CELL LINE; UTERINE CERVIX TUMOR; VIROLOGY;

ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CELL EXTRACTS; CELL LINE, TUMOR; CHICKENS; FEMALE; FOWLPOX VIRUS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; RABBITS; RECOMBINATION, GENETIC; REPRESSOR PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TH2 CELLS; UTERINE CERVICAL NEOPLASMS;

EID: 77951081799     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-40     Document Type: Article

References (60)

1. Wilczynski SP, Bergen S, Walker J, Liao SY, Pearlman LF. Human papillomaviruses and cervical cancer: analysis of histopathologic features associated with different viral types. Hum Pathol 1988, 19:697-704. 10.1016/S0046-8177(88)80176-X, 2837431.
2. Hudson JB, Bedell MA, McCance DJ, Laiminis LA. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 1990, 64:519-526. 249139, 2153221.
3. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989, 8:3905-3910. 402081, 2555178.
4. Duensing S, Münger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004, 109:157-162. 10.1002/ijc.11691, 14750163.
5. Münger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989, 63:4417-4421. 251060, 2476573.
6. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999, 18:7690-7700. 10.1038/sj.onc.1202953, 10618709.
7. Christensen ND, Kreider JW. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol 1990, 64:3151-3156. 249518, 1693698.
8. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991, 185:251-257. 10.1016/0042-6822(91)90772-4, 1656586.
9. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G, . HPV Vaccine Study group Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255. 10.1016/S0140-6736(06)68439-0, 16631880, HPV Vaccine Study group.
10. FUTURE II Study Group Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007, 196:1431-1432. 10.1086/522869, 18008218, FUTURE II Study Group.
11. Tobery TW, Smith JF, Kuklin N, Skulsky D, Ackerson C, Huang L, Chen L, Cook JC, McClements WL, Jansen KU. Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. Vaccine 2003, 21:1539-1547. 10.1016/S0264-410X(02)00679-5, 12615451.
12. Hung CF, Ma B, Monie A, Tsen SW, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther 2008, 8:421-439. 10.1517/14712598.8.4.421, 18352847.
13. Eiben GL, Da Silva DM, Fausch SC, Le Poole IC, Nishimura MI, Kast WM. Cervical cancer vaccines: recent advances in HPV research. Viral Immunol 2003, 16:111-121. 10.1089/088282403322017866, 12828864.
14. Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991, 181:62-69. 10.1016/0042-6822(91)90470-V, 1847269.
15. Schäfer K, Müller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 1999, 81:881-888. 10.1002/(SICI)1097-0215(19990611)81:6<881::AID-IJC8>3.0.CO;2-T, 10362134.
16. Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM, Jarrett WF. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 1993, 74:945-953. 10.1099/0022-1317-74-6-945, 8389809.
17. Chen L, Mizuno MT, Singhal MC, Hu SL, Galloway DA, Hellström I, Hellström KE. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992, 148:2617-2621.
18. Burg SH, Kwappenberg KM, O'Neill T, Brandt RM, Melief CJ, Hickling JK, Offringa R. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001, 19:3652-3660. 10.1016/S0264-410X(01)00086-X, 11395199.
19. Chen CH, Wang TL, Ji H, Hung CF, Pardoll DM, Cheng WF, Ling M, Wu TC. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. Gene Ther 2001, 8:128-138. 10.1038/sj.gt.3301370, 11313782.
20. de Jong A, O'Neill T, Khan AY, Kwappenberg KM, Chisholm SE, Whittle R, Dobson JA, Jack LC, St Clair Roberts JA, Offringa R, Burg SH, Hickling JK. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002, 20:3456-3464. 10.1016/S0264-410X(02)00350-X, 12297390.
21. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, Burg SH, Melief CJ. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002, 169:350-358.
22. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E, Hickling JK, Inglis SC. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347:1523-1527. 10.1016/S0140-6736(96)90674-1, 8684105.
23. Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H, Lipetz C, Evans AS, Mason M. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 2001, 19:2549-2556. 10.1016/S0264-410X(00)00488-6, 11257391.
24. Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC, Stern PL. Immunological and clinical responses inwomen with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003, 63:6032-6041.
25. Baldwin PJ, Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA, Sterling JC. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 2003, 9:5205-5213.
26. Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A, Kitchener HC, Offringa R, Stern PL, Burg SH. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 2004, 10:2954-2961. 10.1158/1078-0432.CCR-03-0703, 15131030.
27. Gissmann L, Nieto K. The Therapeutic Vaccine: Is it Feasible?. Arch Med Res 2009, 40:493-498. 10.1016/j.arcmed.2009.07.003, 19853190.
28. Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccines 2008, 7:889-893. 10.1586/14760584.7.7.889, 18767940.
29. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998, 79:1159-1167.
30. Picard O, Lebas J, Imbert JC, Bigel P, Zagury D. Complication of intramuscular/subcutaneous immune therapy in severely immune-compromised individuals. J Acquir Immune Defic Syndr 1991, 4:641-643.
31. Taylor J, Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine 1988, 6:466-468. 10.1016/0264-410X(88)90091-6, 2854335.
32. Taylor J, Weinberg R, Languet B, Desmettre P, Paoletti E. Recombinant fowlpox virus inducing protective immunity in nonavian species. Vaccine 1988, 6:497-503. 10.1016/0264-410X(88)90100-4, 2854338.
33. Campo MS. Vaccination against papillomavirus in cattle. Clin Dermatol 1997, 15:275-283. 10.1016/S0738-081X(96)00165-4, 9167911.
34. Moore RA, Santos EB, Nicholls PK, White KL, Anderson DM, Lloyd A, Topley P, Romanos M, Thomsen L, Parmar V, Walcott S, Gough GW, Stanley MA. Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles. Virology 2002, 304:451-459. 10.1006/viro.2002.1726, 12504584.
35. Jansen KU, Rosolowsky M, Schultz LD, Markus HZ, Cook JC, Donnelly JJ, Martinez D, Ellis RW, Shaw AR. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995, 13:1509-1514. 10.1016/0264-410X(95)00103-8, 8578834.
36. Leachman SA, Shylankevich M, Slade MD, Levine D, Sundaram RK, Xiao W, Bryan M, Zelterman D, Tiegelaar RE, Brandsma JL. Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J Virol 2002, 76:7616-7624. 10.1128/JVI.76.15.7616-7624.2002, 136350, 12097575.
37. Christensen ND, Kreider JW, Kan NC, DiAngelo SL. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 1991, 181:572-579. 10.1016/0042-6822(91)90890-N, 1707567.
38. Brandsma JL. Animal models of human-papillomavirus-associated oncogenesis. Intervirology 2009, 37:189-200.
39. Georges E, Breitburd F, Jibard N, Orth G. Two Shope papillomavirus-associated VX2 carcinoma cell lines with different levels of keratinocyte differentiation and transplantability. J Virol 1985, 55:246-250. 254922, 2409299.
40. Pozzi E, Zanotto C, Pacchioni S, De Giuli Morghen C, Radaelli A. MHC-restricted CTL assay: an improved method based on naïve and SV40-immortalized rabbit epidermal target cells. J Virol Methods 2009, 155:77-81. 10.1016/j.jviromet.2008.09.029, 18955084.
41. Pozzi E, Basavecchia V, Zanotto C, Pacchioni S, De Giuli Morghen C, Radaelli A. Construction and characterization of recombinant fowlpox viruses expressing human papilloma virus E6 and E7 oncoproteins. J Virol Methods 2009, 158:184-189. 10.1016/j.jviromet.2009.01.021, 19428588.
42. Radaelli A, Zanotto C, Perletti G, Elli V, Vicenzi E, Poli G, De Giuli Morghen C. Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmid and virus-like particles in prime-boost vaccination protocols against SHIV. Vaccine 2003, 21:2052-2064. 10.1016/S0264-410X(02)00773-9, 12706695.
43. Di Bonito P, Grasso F, Mochi S, Accardi L, Donà MG, Branca M, Costa S, Mariani L, Agarossi A, Ciotti M, Syrjänen K, Giorgi C. Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. Infect Agent Cancer 2006, 1:6-14. 10.1186/1750-9378-1-6, 1660559, 17150135.
44. Koutsky LA, Harper DM. Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine 2006, 24:S114-S121.
45. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007, 177:469-479. 1950172, 17671238.
46. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. New Engl J Med 2002, 347:1645-1651. 10.1056/NEJMoa020586, 12444178.
47. Hildesheim R, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007, 298:743-753. 10.1001/jama.298.7.743, 17699008.
48. Hafner N, Driesch C, Gajda M, Jansen L, Kirchmayr R, Runnebaum IB, Dürst M. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 2008, 27:1610-1617. 10.1038/sj.onc.1210791, 17828299.
49. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003, 22:5938-5945. 10.1038/sj.onc.1206894, 12955072.
50. DeFilippis RA, Goodwin EC, Wu L, DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 2003, 77:1551-1563. 10.1128/JVI.77.2.1551-1563.2003, 140828, 12502868.
51. Kanodia S, Da Silva DM, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 2008, 122:247-259. 10.1002/ijc.23252, 17973257.
52. Gissmann L. Modern Uterine Cytopathology 2007, 169-200. ASCP Press, Chicago, Meisels A, Morin C.
53. Meschede W, Zumbach K, Braspenning J, Scheffner M, Benitez-Bribiesca L, Luande J, Gissmann L, Pawlita M. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 1998, 36:475-480. 104563, 9466762.
54. Ghosh AK, Smith NK, Stacey SN, Glew SS, Connor ME, Arrand JR, Stern PL. Serological response to HPV 16 in cervical dysplasia and neoplasia: correlation of antibodies to E6 with cervical cancer. Int J Canc 1993, 53:591-596.
55. Johnston JB, McFadden G. Poxvirus immunomodulatory strategies: current perspectives. J Virol 2003, 77:6093-6100. 10.1128/JVI.77.11.6093-6100.2003, 155018, 12743266.
56. Zanotto C, Pozzi E, Pacchioni S, Volonté L, De Giuli Morghen C, Radaelli A. Canarypox and fowlpox viruses as recombinant vaccine vectors: a biological and immunological comparison. 2009,
57. Baxby D, Paoletti E. Potential use of nonreplicating vectors as recombinant vaccines. Vaccine 1992, 10:8-9. 10.1016/0264-410X(92)90411-C, 1311489.
58. Skinner MA, Laidlaw SM, Eldaghayes I, Kaiser P, Cottingham MG. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev Vaccines 2005, 4:63-76. 10.1586/14760584.4.1.63, 15757474.
59. Ristriani T, Fournane S, Orfanoudakis G, Masson M. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells. Oncogene 2009, 28:762-772. 10.1038/onc.2008.422, 19015633.
60. Massa S, Simeone P, Muller A, Benvenuto E, Venuti A, Franconi R. Antitumor activity of DNA vaccines based on the Human Papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum Gene Ther 2008, 19:354-364. 10.1089/hum.2007.122, 18439124.